Teva announced that the U.S. FDA has approved AJOVYTM injection for the preventive treatment of migraine in adults. AJOVY, a humanized monoclonal antibody that binds to calcitonin gene-related peptide ligand and blocks its binding to the receptor, is the first and only anti-CGRP treatment for the prevention of migraine with quarterly and monthly dosing options.
https://thefly.com/landingPageNews.php?id=2790937
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.